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ABSTRACT While asthma is known to be associated with an increased risk of progressive lung function
impairments and fixed airflow obstruction, there is ongoing debate on whether inhaled corticosteroids
(ICS) modify these long-term risks.
Searches were performed of the PubMed, Embase and CENTRAL databases up to 22 July
2019 for studies with follow-up ⩾1 year that investigated the effects of maintenance ICS on changes in
lung function in asthma.
Inclusion criteria were met by 13 randomised controlled trials (RCTs) (n=11678) and 11 observational
studies (n=3720). Median (interquartile range) follow-up was 1.0 (1–4) and 8.4 (3–28) years, respectively.
In the RCTs, predominantly in individuals with mild asthma, ICS use was associated with improved pre-
bronchodilator (BD) forced expiratory volume in 1 s (FEV1) across all age groups (2.22% predicted (95%
CI 1.32–3.12), n=8332), with similar estimates of strength in association for children and adults.
Improvements in post-BD FEV1 were observed in adults (1.54% (0.87–2.21), n=3970), but not in children
(0.20% (−0.49–0.90), n=3924) (subgroup difference, p=0.006). Estimates were similar between smokers
and nonsmokers. There were no RCT data on incidence of fixed airflow obstruction. In the observational
studies, ICS use was associated with improved pre-BD FEV1 in children and adults. There were limited
observational data for post-BD outcomes.
In patients with mild asthma, maintenance ICS are associated with modest, age-dependent
improvements in long-term lung function, representing an added benefit to the broader clinical actions
of ICS in asthma. There is currently insufficient evidence to determine whether treatment reduces
incidence of fixed airflow obstruction in later life.
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Asthma is a common global disease, affecting over 350 million people, for which many patients are treated
using inhaled corticosteroids (ICS). While the benefits of such treatment have been demonstrated in terms
of asthma control, hospital admissions and mortality, [1–4], the long-term effects of ICS in asthma on
changes in lung function remains unclear. This information is necessary to guide optimal asthma
management, particularly for patients with early-onset persistent disease who are the greatest risk of
progressive lung function impairments [5].
Recent studies have shown that several lung function trajectories lead to fixed airflow obstruction [6, 7]. These
include impaired lung growth in the first two to three decades of life and accelerated lung function decline
from the third decade onwards [6]. Depending on age of onset, asthma is now known to contribute to both
pathways [8, 9]. Given the rising prevalence and global impact of obstructive airways diseases, strategies aimed
at preserving lung function in asthma are urgently needed. There is also growing international interest in this
area, including a European Respiratory Society clinical initiative, CADSET (Chronic Airway Diseases Early
Stratification), which aims to explore the factors that influence lung function trajectories over the lifespan [10].
ICS are currently recommended as a first-line option in persistent asthma [11], and are associated with
improved airway calibre through a reduction in airway inflammation, mucus hypersecretion and bronchial
hyperresponsiveness [12]. To date, the available evidence on their long-term effects on lung function in
asthma have not been adequately summarised. Updates to the Global Initiative for Asthma (GINA)
recommendations in 2019 [13], which now strongly advocate for ICS-containing treatment in all patients
with mild asthma, further increase the need to critically evaluate the evidence on this topic. Therefore, we
aimed to systematically review all studies which have investigated the long-term effects of ICS on lung
function in asthma and to undertake a meta-analysis where similar data were available.
Methods
Search strategy
We conducted systematic searches of the PubMed, EMBASE and CENTRAL databases from inception to
22 July 2019 for peer-reviewed studies. For full details refer to table e1. Reference lists of related review
articles were manually screened for additional studies meeting our inclusion criteria.
Eligibility criteria
We included randomised controlled trials (RCTs) and observational studies with ⩾1year follow-up in
which the effects of maintenance ICS on change in lung function (growth or decline) and risk of fixed
airflow obstruction was assessed. Studies involving either children or adults with current asthma were
included. Studies were required to have an appropriate placebo or control comparison group. Inclusion
was limited to English-language studies published in full text. Studies with concomitant use of
maintenance systemic corticosteroids were excluded.
A range of definitions of asthma were accepted, including physician-diagnosed asthma, spirometrically
defined asthma and survey-reported asthma. Current asthma was defined as: asthma symptoms or
asthma-related healthcare utilisation within the last 12 months.
Outcomes of interest
There were two outcomes of interest. 1) Change in lung function from baseline defined as: change in
forced expiratory volume in 1 s (FEV1), FEV1/forced vital capacity (FVC), forced expiratory flow at
25–75% of FVC (FEF25–75%) or bronchial hyperresponsiveness (BHR). 2) Fixed airflow obstruction defined
as post-bronchodilator (BD) FEV1/FVC ratio <0.7 or less than the lower limit of normal.
Selection of studies
All studies identified in the search strategy were independently screened by two review authors (D.J. Tan
and either D.S. Bui or X. Dai). Full texts of all studies considered eligible, potentially eligible or unclear
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were retrieved and assessed. Disagreements at this stage or further on were settled by consultation with a
third author (D.S. Bui or X. Dai).
Data extraction
Using a standardised data extraction form, study characteristics and outcome data were extracted
independently by two review authors (D.J. Tan and either D.S. Bui or X. Dai). Information extracted
included the first author, date of publication, study design, study setting, date of study, number of
participants, mean age, age range, sex, asthma definition, asthma severity, smoking history, ICS use (type,
frequency, dose and duration), outcome definitions, confounders and interactions, effect estimates and
95% confidence intervals.
Quality assessment and risk of bias
Risk of bias was assessed independently by two review authors (D.J. Tan and either D.S. Bui or X. Dai)
using the Cochrane Collaboration’s Tool for individual RCTs, modified Newcastle–Ottowa scale (NOS) for
individual observational studies [14], and GRADE (Grading of Recommendations Assessment,
Development and Evaluation) guidelines for quality by outcome across a range of studies [15].
Statistical analysis
Where multiple studies reported data for a single outcome on different scales (e.g. % predicted or mL),
standardised mean differences (SMDs) were calculated to enable pooling of the data. If studies presented
data in both formats, data presented as % predicted were selected in preference to mL for conversion to SMD.
RCTs and observational studies were meta-analysed separately. Observational studies were required to have
adjusted for asthma severity and smoking status in the statistical analysis or have accounted for these
factors in their study design (e.g. inclusion criteria of only mild asthma) to be included in the
meta-analysis.
Heterogeneity was assessed using the I2 statistic. Fixed-effects models were used if I2 was <25%.
Random-effects models were used if I2 was between 25% and 75%. Pooled estimates were presented but
considered to be unreliable if I2 was >75%. The selected model for each main outcome was then applied to
any related subgroup meta-analyses. Data were pooled using the program Review Manager, version 5.3 [16].
Subgroup analyses
The following planned subgroup analyses were performed where possible: 1) age group: children (aged
<18 years) versus adults (aged ⩾18 years); 2) atopic status: atopic versus nonatopic; 3) blood or sputum
eosinophil level: high versus low; threshold as specified by the individual studies; 4) smoking status:
current versus never- or former smoker; 5) length of follow-up: RCTs: 1 year versus >1 year; observational
studies: 10 years or <10 versus >10 years.
Sensitivity analyses
The follow sensitivity analyses were performed where possible: 1) risk of bias assessments: with versus
without studies considered at high risk of bias; 2) meta-analysis methodology: fixed-effects models versus
random-effects models.
Protocol registration
The protocol for this systematic review was registered prospectively in the PROSPERO database in
September 2017 (registration number: CRD42017053543). FVC and BHR were added as outcomes of
interest after protocol registration.
Results
Search results
6517 records were identified from the database searches and reference lists of related articles (figure 1). Of
these, 365 records were selected for full-text screening and of these, 38 articles from 24 unique studies met
the pre-specified inclusion criteria. Excluded records and their reasons for exclusion are listed in table e2.




13 RCTs with a total of 11678 participants were included [12, 17–27]. Five RCTs were performed in children
(n=1250) [18, 21, 23, 26, 27], seven in adults (n=3263) [12, 17, 19, 20, 22, 24, 25] and one in both children
and adults (n=7165) [3]. Three studies contributed 90% of the participants (START: n=7165; SYGMA1:
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n=2559; CAMP: n=729) [3, 24, 27]. Asthma was physician-diagnosed in all studies. BHR or bronchodilator
reversibility was an additional inclusion criterion in nine studies (n=10889) [3, 19, 20, 22–27]. Seven studies
were in individuals with mild asthma (n=10708) [3, 17–19, 21, 24, 26], two were in individuals with
mild-to-moderate asthma (n=764) [12, 27], one was in individuals with moderate-to-severe asthma (n=54)
[23], and three did not limit inclusion by asthma severity (n=152) [20, 22, 25]. Eight studies used budesonide
(n=11128) [3, 17, 21–25, 27], three used fluticasone (n=149) [12, 19, 20] and two used beclomethasone
(n=401) [18, 26]. Based on GINA criteria [11], ICS were categorised as low dose in eight studies (n=10459)
[3, 17, 19–22, 24, 25], medium dose in four studies (n=1184) [18, 23, 26, 27] and high dose in one study
(n=35) [12]. Median (interquartile range) follow-up was 1.0 (1–4) years.
Risk of bias assessments
Methodological quality in the RCTs was good overall (figure 2). All RCTs were assessed to be at low risk
of selection, performance and detection bias. Five studies were assessed to be at high risk of attrition bias,
related to high dropout rates [19–21, 23, 25]. Reporting bias was unclear in eight mainly older studies for
which prospective protocols were not available [18–23, 25, 26]. GRADE certainty of evidence across
outcomes ranged from low to high as outlined in tables 2 and 3.
Studies excluded from the quantitative analysis
Two small RCTs were excluded from the quantitative analysis due to methodological factors or
nonrepresentative study samples [20, 23]. One study compared budesonide to placebo in 47 children with
moderate-to-severe asthma, but had significant and selective dropout in the placebo arm, which resulted in
early discontinuation [23]. The budesonide arm was continued to study completion at 3 years and the
authors did not account for differences in treatment duration in the comparisons. The second study was
published as a brief report and compared fluticasone to placebo in 45 adults with asthma and accelerated
FIGURE 1 PRISMA flow diagram for
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BEASLEY [17] Adults 1 Physician-diagnosed
asthma; treatment





225 34.9 57 90.3
No placebo
(open-label)
223 35.8 51 89.2







119 7.6 32.8 1.39 91.3
Placebo, twice
daily
121 7.7 34.7 1.42 92.0





35 27 54.2 3.55 97.2
Placebo daily 34 26 69.7 3.33 98.5
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asthma; ⩾1
exacerbation in last




32 10.0 46.9 2.23 102.1
Placebo daily 34 9.4 35.3 2.04 104.6
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Placebo twice
daily
16 35.1 56.3 92.1
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daily
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daily











3597 24.0 54.2 86.3
Placebo daily 3568 24.0 54.0 86.6







81 9.6 41.0 1.89 92.0
Placebo twice
daily
80 9.5 45.0 1.88 96.0





311 9.0 41.8 93.6
Placebo, twice
daily
418 9.0 44.0 94.2
Continued
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lung function decline (>80 mL·year−1) [20]. The study sample was considered to be highly selected due the
declining lung function inclusion criteria and not representative of the general asthma population.
Pre-BD lung function
Pre-BD FEV1
Eight studies measured changes in pre-BD FEV1 (% pred) (table 2, figure 3) [3, 12, 19, 21, 22, 25–27].
Improvements were observed with treatment across all age groups (2.22% (95% CI 1.32–3.12), n=8332),
with similar estimates of strength in association in children (2.08% (95% CI 0.71–3.44), n=4151) and
adults (2.47% (95% CI 1.64–3.29), n=4181). Findings were similar in four studies which measured pre-BD
FEV1 in mL (74 mL (95% CI 54–94), n=3603) [18, 24, 25, 27] and when SMDs were calculated and
pooled (0.21 SMD (95% CI 0.12–0.30), n=11131).
Pre-BD FVC
Two studies measured changes in pre-BD FVC (% pred) and found no evidence of a treatment benefit
(0.10% (95% CI −1.23–1.43), n=804) [25, 27]. Findings were similar in two studies which reported pre-BD
FVC in mL (−13 mL (95% CI −149–124), n=804) [25, 27] and when SMD were calculated and pooled
(0.01 SMD (95% CI −0.13–0.15), n=804)
Pre-BD FEV1/FVC
No studies measured changes in pre-BD FEV1/FVC (% pred). One study performed in children measured
change in pre-BD FEV1/FVC (ratio multiplied by 100) and found significant improvements with treatment
(1.60 (95% CI 0.64–2.56), n=729) [27].
Pre-BD FEF25–75
One study measured changes in pre-BD FEF25–75%, but was excluded from the quantitative analysis due to




One study in adults [3] and two in children [3, 27] measured changes in post-BD FEV1 (% pred) (table 3,
figure 4). Significant improvements were observed with treatment in adults (1.54% (95% CI 0.87–2.21),
n=3970), but not in children (0.20% (95% CI −0.49–0.90), n=3924) (p-subgroup differences0.006). One
study reported change in post-BD FEV1 (mL) in children and also did not demonstrate a treatment benefit
(−40 mL (95% CI −115–35, n=729) [27]. Findings were similar when SMD were calculated and pooled,
with benefits found in adults (0.14 SMD (95% CI 0.08–0.21), n=3970), but not in children (0.02 SMD
(95% CI −0.05–0.09), n=4924).
Post-BD FVC
One study performed in children measured changes in post-BD FVC (% pred) and found no evidence of
treatment benefit (−0.20% (95% CI −1.40–1.00), n=729) [27]. The same study also measured changes in
post-BD FVC (mL) and a borderline adverse effect of treatment would have been reported if this measure
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ICS: inhaled corticosteroid; BD: bronchodilator; FEV1: forced expiratory volume in 1 s; SABA: short-acting β2-agonist; BHR: bronchial
hyperresponsiveness; BDR: bronchodilator reversibility; FVC: forced vital capacity. #: low-dose ICS; ¶: medium-dose ICS; +: high-dose ICS.
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Post-BD FEV1/FVC
No studies measured changes in post-BD FEV1/FVC (% pred). One study in children measured change in
post-BD FEV1/FVC (ratio) and found an association in the direction of a benefit (0.70 (95% CI −0.08–
1.48), n=729), although this did not reach statistical significance [27].
Post-BD FEF25–75%
One study measured changes in post-BD FEF25–75%, but was excluded from the quantitative analysis due
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FIGURE 2 Cochrane Collaboration Tool (randomised controlled trials): risk of bias assessments for each
included study.
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Fixed airflow obstruction
There were no RCTs that reported data on incidence of fixed airflow obstruction.
BHR
Three studies measured BHR as change in doubling concentrations of methacholine provocative
concentration causing a 20% fall in FEV1 (PC20) [19, 21, 22]. Treatment increased methacholine PC20
compared to placebo (1.07 doubling concentrations (95% CI 0.65–1.49), n=223). Findings were similar
when BHR was expressed as change in methacholine PC20 mg·mL
−1 (0.99 (95% CI 0.32–1.66), n=161) [26],
change in methacholine PC20 factor increase from baseline (1.10× (95% CI 0.61–1.59), n=729) [27] and
change in histamine PC20 factor increase from baseline (2.59× (95% CI 1.18–4.00), n=75) [25].
Subgroup analyses
Stratification by smoking status
The largest study (START) reported changes in pre-BD and post-BD lung function stratified by smoking
status. No significant differences were found between smokers and nonsmokers for change in either
pre-BD FEV1 (p-subgroup difference0.22) or post-BD FEV1 (p-subgroup difference0.37) [3].
Stratification by duration of follow-up
When stratified by duration of follow-up, the greatest benefits for pre-BD FEV1 were found in the first
year of follow-up [18, 19, 22, 24, 25] when compared to studies with follow-up >1 year [3, 27]
(p-subgroup differences0.004) (figure e1). Stratification for post-BD lung function by follow-up could not
be performed as all studies had follow-up durations >1 year.
Other pre-specified subgroup analyses
No studies provided outcome data for the other pre-specified subgroup analyses by atopic status, blood or
sputum eosinophil counts.
TABLE 2 Meta-analysis of randomised controlled trials for pre-bronchodilator (BD) outcomes stratified by age group
Outcome or subgroup Studies n Participants n Statistical method Effect estimate p-value I2 GRADE
ΔPre-BD FEV1 % pred 8 8332 MD (Random, 95% CI) 2.22 (1.32–3.12) <0.0001 41% Moderate
#
Adults 5 4181 MD (Random, 95% CI) 2.47 (1.64–3.29) <0.0001 0% High
Children 4 4151 MD (Random, 95% CI) 2.08 (0.71–3.44) 0.003 64% Moderate#
ΔPre-BD FEV1 mL 4 3603 MD (Random, 95% CI) 74.14 (54.47–93.81) <0.0001 87% Moderate
#
Adults 2 2634 MD (Random, 95% CI) 108.82 (84.40–133.23) <0.0001 0% High
Children 2 969 MD (Random, 95% CI) 10.00 (−23.21–43.21) 0.56 0% Moderate#
ΔPre-BD FEV1 SMD 10 11131 SMD (Random, 95% CI) 0.21 (0.12–0.30) <0.0001 68% Moderate
#
Adults 6 6740 SMD (Random, 95% CI) 0.28 (0.15–0.41) <0.0001 63% Moderate#
Children 5 4391 SMD (Random, 95% CI) 0.16 (0.04–0.28) 0.008 60% Moderate#
ΔPre-BD FVC % pred 2 804 MD (Fixed, 95% CI) 0.10 (−1.23–1.43) 0.88 0% Moderate#
Adults 1 75 MD (Fixed, 95% CI) 2.30 (−2.29–6.89) 0.33 Low#,
¶
Children 1 729 MD (Fixed, 95% CI) −0.10 (−1.49–1.29) 0.89 Low#,
¶
ΔPre-BD FVC mL 2 804 MD (Random, 95% CI) −12.84 (−149.33–123.65) 0.85 53% Moderate#
Adults 1 75 MD (Random, 95% CI) 90.00 (−100.51–280.51) 0.35 Low#,
¶
Children 1 729 MD (Random, 95% CI) −60.00 (−124.87–4.87) 0.07 Low¶,
¶
ΔPre-BD FVC SMD 2 804 SMD (Fixed, 95% CI) 0.01 (−0.13–0.15) 0.86 0% Moderate#
Adults 1 75 SMD (Fixed, 95% CI) 0.23 (−0.23–0.68) 0.33 Low#,
¶
Children 1 729 SMD (Fixed, 95% CI) −0.01 (−0.16–0.14) 0.89 Low#,
¶
ΔPre-BD FEV1/FVC % pred 0 0 MD (Fixed, 95% CI)
Adults 0 0 MD (Fixed, 95% CI)
Children 0 0 MD (Fixed, 95% CI)
ΔPre-BD FEV1/FVC ratio 1 729 MD (Fixed, 95% CI) 1.60 (0.64–2.56) 0.001 Moderate
#
Adults 0 0 MD (Fixed, 95% CI)
Children 1 729 MD (Fixed, 95% CI) 1.60 (0.64–2.56) 0.001 Moderate#
ΔPre-BD FEV1/FVC SMD 1 729 SMD (Fixed, 95% CI) 0.25 (0.10–0.39) 0.001 Moderate
#
Adults 0 0 SMD (Fixed, 95% CI)
Children 1 729 SMD (Fixed, 95% CI) 0.25 (0.10–0.39) 0.001 Moderate#
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; MD: mean difference; SMD: standardised mean difference.
#: GRADE score
downgraded for heterogeneity or inconsistency of results between studies; ¶: GRADE score downgraded for imprecision, 95% CI includes
important benefit and potential harm.
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Sensitivity analyses
Sensitivity analyses performed by meta-analysis model and risk of bias assessment did not significantly
affect the results for pre-BD or post-BD lung function (table e4).
Observational studies
Included studies
11 observational studies with a total of 3720 participants were included [28–37]. Four studies were in
children (n=787) [28, 30, 34, 36] and seven in adults (n=2933) [29, 31–33, 35, 37, 38]. Asthma was
physician-diagnosed in eight studies (n=1044) [28, 30–34, 36, 37] and self-reported in three studies
(n=2676) [29, 35, 38]. ICS use was measured at baseline in five studies (n=750) [28, 31, 32, 34, 36], at
follow-up in four studies (n=2663) [29, 30, 37, 38], and at both baseline and follow-up in two studies
(n=307) [33, 35]. BHR or bronchodilator reversibility was required as an additional inclusion criterion in
five studies (n=2108) [29, 31, 32, 34, 37]. Asthma was of mild-to-moderate severity in two studies (n=301)
[28, 37] and the remaining nine did not restrict inclusion by asthma severity (n=3419). Median
(interquartile range) follow-up was 8.4 (3–28) years.
Quality assessment
Methodological quality of the cohort studies varied (table e5), with a median (interquartile range) NOS
score of 7 (4–9). Three studies were assessed as being of “very good” quality (NOS ⩾9) [35, 36, 38], three
of “good” quality (NOS 7–8) [28, 31, 33], four of “satisfactory” quality (NOS 5–6) [29, 32, 34, 37], and
one of “unsatisfactory” quality (NOS 0–4) [30]. Quality was most often negatively impacted by inadequate
adjustment for critical confounders (i.e. asthma severity and smoking status). Six studies also had high
rates of loss to follow-up or selective patterns of dropout in the comparison groups [29, 30, 33, 35, 37, 38].
TABLE 3 Meta-analysis of randomised controlled trials for post-bronchodilator (BD) outcomes stratified by age group
Outcome or subgroup Studies n Participants n Statistical method Effect estimate p-value I2 GRADE
ΔPost-BD FEV1 % pred 2 7894 MD (Random, 95% CI) 0.61 (−0.31–1.54) 0.19 71% Moderate#
Adults 1 3970 MD (Random, 95% CI) 1.54 (0.87–2.21) <0.0001 Moderate#
Children 2 3924 MD (Random, 95% CI) 0.20 (−0.49–0.90) 0.57 12% High
ΔPost-BD FEV1 mL 1 729 MD (Fixed, 95% CI) −40.00 (−115.38–35.38) 0.30 Moderate#
Adults 0 0 MD (Fixed, 95% CI)
Children 1 729 MD (Fixed, 95% CI) −40.00 (−115.38–35.38) 0.30 Moderate#
ΔPost-BD FEV1 SMD 2 8894 SMD (Random, 95% CI) 0.06 (−0.03–0.15) 0.18 69% Moderate#
Adults 1 3970 SMD (Random, 95% CI) 0.14 (0.08–0.21) <0.0001 Moderate#
Children 2 4924 SMD (Random, 95% CI) 0.02 (−0.05–0.09) 0.57 15% High
ΔPost-BD FVC % pred 1 729 MD (Fixed, 95% CI) −0.20 (−1.40–1.00) 0.74 Low#,
¶
Adults 0 0 MD (Fixed, 95% CI)
Children 1 729 MD (Fixed, 95% CI) −0.20 (−1.40–1.00) 0.74 Low#,
¶
ΔPost-BD FVC mL 1 729 MD (Fixed, 95% CI) −60.00 (−119.99–−0.03) 0.05 Low#,
¶
Adults 0 0 MD (Fixed, 95% CI)
Children 1 729 MD (Fixed, 95% CI) −60.00 (−119.99–−0.03) 0.05 Low#,
¶
ΔPost-BD FVC SMD 1 729 SMD (Fixed, 95% CI) −0.02 (−0.17–0.13) 0.77 Low#,
¶
Adults 0 0 SMD (Fixed, 95% CI)
Children 1 729 SMD (Fixed, 95% CI) −0.02 (−0.17–0.13) 0.77 Low#,
¶
ΔPost-BD FEV1/FVC % pred 0 0 MD (Fixed, 95% CI)
Adults 0 0 MD (Fixed, 95% CI)
Children 0 0 MD. (Fixed, 95% CI)
ΔPost-BD FEV1/FVC ratio 1 729 MD (Fixed, 95% CI) 0.70 (−0.08–1.48) 0.08 Low#,
¶
Adults 0 0 MD (Fixed, 95% CI)
Children 1 729 MD (Fixed, 95% CI) 0.70 (−0.08–1.48) 0.08 Low#,
¶
ΔPost-BD FEV1/FVC SMD 1 729 SMD (Random, 95% CI) 0.13 (−0.01–0.28) 0.07 Low#,
¶
Adults 0 0 SMD (Random, 95% CI)
Children 1 729 SMD (Random, 95% CI) 0.13 (−0.01–0.28) 0.07 Low#,
¶
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; MD: mean difference; SMD: standardised mean difference.
#: GRADE score
downgraded for heterogeneity or inconsistency of results between studies; ¶: GRADE score downgraded for imprecision, 95% CI includes
important benefit and potential harm.
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Studies excluded from the quantitative analysis
Seven observational studies were excluded from the quantitative analysis as critical confounders (asthma
severity and smoking status) were not adjusted for in the statistical analysis or through study design
[28–32, 34, 37]. Sensitivity analyses with these studies included are provided in table e6. Of the remaining
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2.22 (1.32–3.12)Total (95% CI)
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FIGURE 3 Forest plot comparison (randomised controlled trials): change in pre-bronchodilator forced expiratory volume in 1 s (% predicted)
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0.61 (–0.31–1.54)Total (95% CI)
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FIGURE 4 Forest plot comparison (randomised controlled trials): change in post-bronchodilator forced expiratory volume in 1 s (% predicted)
stratified by age. ICS: inhaled corticosteroid.
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Pre-BD lung function
Sufficient data to perform a meta-analysis were available for only one outcome, pre-BD FEV1 (mL), with
three studies, all performed in adults, finding significant per-year treatment benefits over their follow-up
periods (14 mL·year−1 (95% CI 2–26), n=939) [33, 35, 38]. One study, performed in children also found
treatment benefits in pre-BD FEV1 (% pred) (0.81% per year (95% CI 0.01–1.61), n=190) [36].
Post-BD lung function
None of the four studies measured post-BD outcomes or incidence of fixed airflow obstruction.
Subgroup analyses
Stratification by smoking status
One observational study reported data on pre-BD FEV1 stratified by smoking status [35]. Similar to the
START trial, this study found no significant differences between smokers and nonsmokers.
Other pre-specific subgroup analyses
No observational studies provided data for other pre-specified subgroup analyses by atopic status, blood or
sputum eosinophil counts, or duration of follow-up.
Sensitivity analyses
Sensitivity analyses performed by meta-analysis model and risk of bias assessment did not significantly
affect the results for pre-BD outcomes (table e6). There were insufficient studies to perform sensitivity
analyses for post-BD outcomes.
Discussion
This is the first systematic review to comprehensively evaluate the long-term effects of ICS on lung
function in patients with asthma. Within the RCTs, maintenance ICS was associated with modest
improvements in pre-BD FEV1 across all age groups, whereas improvements in post-BD FEV1 were
observed only in adults. The greatest benefits were observed in the first year of treatment, and estimates
were similar between smokers and nonsmokers. Due to the characteristics of the included studies, these
findings are most applicable to children and adults with mild asthma treated with low-dose ICS. However,
we found no RCT data on the effect of ICS on incidence of fixed airflow obstruction in asthma. Moreover,
while the observational studies were generally of longer duration, many were assessed as being at high risk
of bias due to inadequate adjustment for confounding factors.
Current asthma guidelines recommend ICS as a first-line option for persistent asthma. ICS therapy improves
asthma control, reduces exacerbations and provides a modest increase in short-term measures of lung
function over weeks to months [2, 3, 39, 40]. While we found these benefits on lung function persisted
beyond the first year of treatment, the magnitude of benefit was relatively modest and below conventional
minimally clinically important difference cut-offs for FEV1 (230 mL) [41]. Additionally, in the subgroup
analysis by duration of follow-up, the greatest benefits were obtained within the first year and then appeared
to decrease with time. This trend was similarly observed in START (year 1 versus year 3) and CAMP (year 1
versus year 4) [3, 27]. However, it should be noted that this observation was confounded by several
time-dependent factors, including decreasing compliance to ICS with time in the intervention arms and
increasing use of nonintervention asthma medications in the placebo arms [3, 24, 27]. Therefore, rather than
a cumulative benefit on lung function over time in these mild asthma trials, we found that maintenance ICS
use was associated with a modest absolute benefit which was maintained to an extent with continued
treatment. These effects could be more pronounced in patients with moderate-to-severe disease and in those
receiving higher-dose ICS. However, there were limited data to evaluate such effects in these subgroups.
The age-based differences for post-BD FEV1 were unexpected. In meta-analyses with small numbers of
contributing trials, subgroup differences can arise from subtle differences in methodology and this was
important to exclude. However, the majority of the data for this outcome, for both children and adults,
came from one large study (START), which recruited patients using standardised methodology across age
groups [3]. CAMP also contributed data on post-BD FEV1 and did not identify a treatment benefit in
children [27], despite their participants having a slightly higher disease severity at baseline than participants
in START (mild-to-moderate versus mild only) [27]. While there appeared to be a trend toward a benefit
with treatment on post-BD FEV1/FVC in CAMP, this did not reach statistical significance.
Several reasons may account for these age-based differences. First, the diagnosis of asthma in children is
often less clear than in adults and physician-diagnosed asthma in the absence of objective tests can be
uncertain [42, 43]. Inclusion of children who may not have benefited from ICS in the first place, such as
those with viral-induced or episodic wheeze, would have reduced any observed treatment benefit.
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Secondly, childhood asthma often improves over adolescence and treatment differences could also have
been reduced by improved asthma control or asthma remission as part of the natural course [44]. This
theory is supported by data from START, in which adolescents (aged 11–17 years) were less likely to
benefit from maintenance ICS compared to both younger children (aged 5–10 years) and adults (aged 18–
66 years). Lung function trajectory studies have also shown that small deficits established early in life can
diminish with time, with some children with below-normal lung function entering a “catch-up” phase
during puberty [7, 45]. Consequently, rapid growth in lung function during childhood might also explain
the observed treatment differences between children and adults.
While the observational studies had longer durations of follow-up compared to the RCTs, few met
pre-specified criteria to be included in the quantitative analysis. Of those included, ICS use was variably
assessed at baseline and/or follow-up, and change in medication use between these time-points were not
clearly assessed. Acknowledging these important limitations, ICS use as defined in these observational
studies was associated with improved trends in pre-BD FEV1 across the follow-up periods, which ranged
from 9 to 13 years. The observational studies were also more likely to have observed any effects of ICSs on
fixed airflow obstruction in asthma, which may develop over years to decades [7]. Unfortunately, we did
not identify any studies reporting data for this outcome.
The effects of ICSs on lung function in asthma appear to be mediated, at least in part, through an effect
on asthma exacerbations. Exacerbations represent intermittent periods of intense airways inflammation,
and have been associated with structural airways remodelling and rapid lung function decline [46, 47]. In a
post hoc analysis of START, O’BYRNE et al. [47] showed that low-dose budesonide attenuated these adverse
effects, with treatment associated with a reduction in both the rate and impact of severe exacerbations on
post-BD FEV1. While budesonide was not found to improve post-BD FEV1 in children in the overall
analysis, treatment was associated with a significant reduction in post-BD FEV1 impairment in children
who experienced one or more severe exacerbations during the 3-year follow-up (−2.38% predicted on
budesonide versus −6.29% predicted on placebo). This interaction, also observed in adults, supports the
hypothesis that treatment effects are likely to be greater in patients with more severe disease.
Following completion of the recent SYGMA1 and Novel START trials, there is now strong evidence on the
benefits of maintenance ICSs compared to short-acting β-agonist (SABA) reliever monotherapy for
exacerbation prevention in mild asthma [17, 24]. Accordingly, the 2019 GINA update has now
recommended against SABA reliever monotherapy in mild asthma, and instead recommends ICS
containing treatment for all mild asthma patients. With new evidence supporting the use of as-needed
budesonide–formoterol as an alternative to maintenance ICS in step 2 treatment [13, 17, 24, 48], the
relative effects of these regimens on long-term lung function should also be examined.
This systematic review has a number of key strengths. We performed comprehensive searches of three
electronic databases and two authors independently screened references, extracted data and performed
quality assessments. We also evaluated both experimental and observational evidence. The RCTs provided
higher quality evidence but recruited highly selected samples of asthma patients suited for drug efficacy
trials. In contrast, the observational studies evaluated a broader range of asthma patients over longer
durations of follow-up. Given the strong existing evidence base and ethical implications, we believe there
are unlikely to be further placebo-controlled trials conducted. However, high-quality observational data on
the longer term effects of ICS treatment in moderate-to-severe asthma, particularly for post-BD lung
function, are still required
This review also had several limitations. First, one of our objectives of examining the effect of ICS on
incidence of fixed airflow obstruction in asthma could not be achieved due to the lack of available
evidence. Secondly, our review was limited to English language publications and relevant non-English
studies may have been excluded. Thirdly, the Cochrane Collaboration now recommends the ROBINS-I
tool for assessing risk of bias in nonrandomised studies [49] and while limited observational data were
included, risk of bias assessments for these studies were performed using the formerly recommended NOS
tool [14]. Fourthly, many of the included studies compared low-dose budesonide to placebo and recruited
only patients with mild asthma. Therefore, our results may not be representative of more severe asthma,
higher-dose or other ICS agents. Fifthly, most data for several outcomes came from one large RCT
(START), which included patients with recent-onset asthma. It is unclear whether outcomes in this sample
may have been more pronounced compared to patients with longer term established disease. Finally, most
studies focused on changes in FEV1. Other routinely collected spirometry indices (e.g. FVC and FEV1/
FVC) were infrequently reported, which raised concerns of selective reporting for these outcomes.
In conclusion, maintenance ICS are associated with modest, age-dependent improvements in long-term
lung function in patients with mild asthma. These improvements represent an added functional benefit to
the more accepted clinical actions of ICS and reinforce the importance of ICS as a recommended initial
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treatment option even for mild asthma. Further research is still needed to determine whether ICS use
modifies the risk of developing fixed airflow obstruction in asthma, especially in smokers and high-quality
observational data from existing prospective cohorts could be used to address these important knowledge
gaps. Treatment adherence, correct inhaler technique and correct diagnosis of asthma are factors likely to
influence these outcomes in real-world settings.
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